The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by Barclays on August 14, 2024. The analyst firm set a price target for $3.00 expecting VOR to rise to within 12 months (a possible 158.62% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Vor Biopharma (NASDAQ:VOR) was provided by Barclays, and Vor Biopharma maintained their overweight rating.

There is no last upgrade for Vor Biopharma

There is no last downgrade for Vor Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vor Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vor Biopharma was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Vor Biopharma (VOR) rating was a maintained with a price target of $10.00 to $3.00. The current price Vor Biopharma (VOR) is trading at is $1.16, which is out of the analyst’s predicted range.